

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **LifeTech Scientific Corporation**

**先健科技公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1302)**

### **Positive Profit Alert**

This announcement is made by the board (the “**Board**”) of directors of LifeTech Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2021 and the information currently available to the Board, the Group is expected to record no less than RMB200.0 million in profit attributable to owners of the Company, representing an increase ranging from 100% to 110% for the six months ended 30 June 2021 as compared to the corresponding period in 2020, and an increase ranging from 110% to 120% as compared to the corresponding period in 2019.

Such significant increase in profit attributable to owners of the Company was primarily attributable to (i) an increase in the sales revenue and gross profit from each business segment of the Group, its overall gross profit recorded an increase ranging from 70% to 75% as compared to the corresponding period in 2020; and (ii) the investment income generated from Ally Bridge Group Innovation Capital Partners III, L.P. was approximately RMB27.7 million for the six months ended 30 June 2021, representing an increase of approximately RMB17.7 million as compared to the corresponding period in 2020.

The Board reminds Shareholders and potential investors that the information contained in this announcement is only based on a preliminary assessment made by the Board with reference to the unaudited management accounts of the Group currently available to the Board, and is not based on any figure or information which has been audited or reviewed by the Company's independent auditors and may be subject to adjustments and changes. Shareholders and potential investors are advised to refer to the details of the Group's interim results announcement for the half-year ended 30 June 2021, which is expected to be published by the end of August 2021.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**LifeTech Scientific Corporation**  
**XIE Yuehui**  
*Executive Director, Chairman  
and Chief Executive Officer*

Hong Kong, 21 July 2021

*As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors of the Company; Mr. JIANG Feng being non-executive Director of the Company; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors of the Company.*